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Abstract 
The efficacy of vaccines targeting SARS-CoV-2 is becoming apparent now that the mRNA 
and adenovirus vector vaccines that have been approved for emergency use are showing 
promise.  However, the longevity of the protective immune response and its efficacy against 
emerging variants remains to be determined.  To improve longevity and future protection 
against variants, we have designed a DNA vaccine encoding both the SARS-CoV-2 spike 
(S) protein receptor-binding domain (RBD) and its nucleocapsid (N) protein, the latter of 
which is highly conserved amongst beta coronaviruses.  The vaccine elicits strong pro-
inflammatory CD4 Th1 and CD8 T-cell responses to both proteins, with these responses 
being significantly enhanced by fusing the nucleocapsid sequence to a modified Fc domain.  
We have shown that the vaccine also stimulates high titre antibody responses to RBD which 
efficiently neutralise in both a pseudotype and live virus neutralisation assay and show cross 
reactivity with S proteins from the emerging variants Alpha (B.1.1.7) and Beta (B.1.351).  
This DNA platform can be easily adapted to target variant RBD and N proteins and we show 
that a vaccine variant encoding the B.1.351 RBD sequence stimulates cross-reactive 
humoral and T-cell immunity. These data support the translation of this DNA vaccine 





The current SARS-CoV-2 pandemic has prompted a global response with researchers from 
hundreds of institutions across the world developing and testing potential vaccine candidates 
that can prevent infection and COVID-19 disease.  SARS-CoV-2 is known to facilitate host 
cell entry by targeting the cellular receptor, ACE2 using its densely-glycosylated spike (S) 
protein. The S protein is a trimeric class I fusion protein which undergoes several structural 
rearrangements and cleavage events to eventually fuse the viral and host membranes [1, 2], 
a process triggered by S1 subunit binding to the host cell receptor ACE2 via its receptor 
binding domain (RBD).  The virus targets the airway epithelial cells, alveolar epithelial cells, 
vascular endothelial cells and macrophages in the lung, all of which express ACE2 [3, 4].  
Viral assembly inside the host cell requires four structural proteins, the S, matrix (M), 
envelope (E), and nucleocapsid (N) proteins.  Homotrimers of the S protein make up the 
receptor-binding spikes on the viral surface [5, 6].  The N protein contains two domains that 
each bind the viral genome, packaging it into virions [11-13].  SARS-CoV-2 has a single-
stranded positive sense RNA genome and the coronavirus family have the largest genomes 
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in this category of viruses, encoding RNA processing and editing enzymes which increase 
the fidelity of replication.  However, variation arises through a high rate of homologous 
recombination.  Although SARS-CoV-2 can cause severe symptoms and death in the elderly 
or clinically vulnerable populations, the fact that approximately 80% of infected individuals 
present with no symptoms or mild infection [14] suggests that effective immunity can control 
the infection.    
 
As the S protein has been shown to be the primary target for neutralising antibodies in 
patients with SARS-CoV-2 [15], it has been the focus of most vaccine development 
programmes. Although, the S protein is also a key target for T cell responses, responses 
have also been detected against the M, E and N proteins and several other non-structural 
proteins [16].  The currently approved SARS-CoV-2 vaccines and most of those under 
development predominantly aim to stimulate neutralising antibody responses against the S 
protein to block the virus binding to ACE2 receptor and entering cells.  However, viral 
evolution has created numerous mutations in the S protein that not only have increased 
infectivity but have also reduced the efficacy of neutralising antibodies that have been raised 
to previously encountered viruses [17-20].  The N protein plays a vital role in viral RNA 
replication and the formation of new virions and is therefore highly conserved between 
coronaviruses [4, 21].  It is present in large quantities and can stimulate a strong immune 
response.  Critically, most survivors of SARS-CoV-2 show evidence of T cell and antibody 
immunity against the N protein [22], suggesting that it is a target of the natural immune 
response.  Our vaccine design includes the N protein in order to provide broader immunity 
during the ongoing viral pandemic, a strategy also being considered by other next generation 
vaccine developers [23]. 
 
We have previously shown that delivery of epitopes from tumour antigens, linked to human 
immunoglobulin G1 (IgG1) fragment crystallisable (Fc) in a DNA vector, stimulates high 
avidity CD8 T cell responses that are efficiently recruited into the memory pool [24-26].  The 
DNA vector enables direct presentation of the encoded epitopes in antigen presenting cells 
(APCs) as well as cross presentation of secreted Fc-fused proteins to dendritic cells via high 
affinity FcγR1 receptor (CD64) binding.  This DNA vaccine platform has been successfully 
used in the clinic as a cancer immunotherapeutic, where it has shown to induce vaccine-
specific T-cell responses in patients with melanoma and was compatible with a prime and 
multiple boosts dosing regimen [27].  Additionally, we have recently described an Fc-
engineering approach which increases the functional avidity of antibody target binding by 
enhancing Fc:Fc cooperativity  [28] and this modified Fc forms part of our vaccine design.  
Herein, we describe the validation of this versatile and rapid to manufacture DNA platform 
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for the generation of a SARS-CoV-2 vaccine targeting both the N protein and the S  RBD .  
We report that the linkage of the N protein to the modified Fc enhances T cell immunity, and 
show that the inclusion of this N-modified Fc fusion alongside the RBD antigen in a bivalent 
DNA vector stimulates strong cellular and humoral immunity to both antigens.  High titre 
antibody responses that exhibited pseudotype neutralisation with a 50% reduction in 
infective dose (ID50) of >5000 were induced.  High frequency CD8 and Th1 CD4 T cell 
responses to both RBD and N proteins were stimulated.  Finally, we demonstrate the 
induction of variant cross-reactive immune responses and the flexibility of this DNA platform 
for targeting SARS-CoV-2 variants.  Collectively, these results underpin the advancement of 




The backbone of the vaccine plasmids was derived from the FDA regulatory compliant 
vector backbone of pVAX1 (Invitrogen) for use in humans.  All nucleotide sections for 
insertion were codon optimised for expression in humans and contain a human IgH leader 
(MDWIWRILFLVGAATGAHS). Codon-optimised nucleotide sections encoding the leader, 
amino acids (aa) of the S glycoprotein RBD domain 319–541 or 330–525 (GenBank 
accession number YP_009724390, isolate Wuhan-Hu-1) alone, fused in frame with either 
the Hinge-CH2-CH3 domain of the human IgG1 Fc constant region (GenBank accession 
number P01857) or the variant Hinge-CH2-CH3 iV1 (where 23 amino acids (aa) have been 
replaced with murine IgG3 residues) or attached to a fibritin trimer fold on 
(GYIPEAPRDGQAYVRKDGEWVLLSTFL) or disulphide bridge motif (CCGGGSG) via a 
glycine serine linker were synthesised with BamHI and XhoI sites inserted at the 5′ and 
3′ends respectively.  In the first round of cloning, these sections were inserted into the 
BamHI/XhoI sites of the pVaxDCIB68 (SCIB1) plasmid as described previously [24, 29], in 
direct replacement of the SCIB1 light kappa chain in the first expression cassette to generate 
intermediate plasmids.  
 
In a second round of cloning codon-optimised nucleotide sections encoding the leader, full-
length nucleoprotein aa 2–419 (Accession number YP_009724397) alone or fused in frame 
with the Hinge-CH2-CH3 domain of the human IgG1 constant domain or the variant Hinge-
CH2-CH3iV1 were synthesised and flanked with HindIII/PstI.  The heavy chain was excised 
using HindIII/PstI from the intermediate vectors generated from the first round and replaced 
with the N protein sections in the second expression cassette alongside the appropriate S 
section (Figure 1A).  The sequences of both chains within each expression cassette of the 
pVaxDC vectors were confirmed by the dideoxy chain termination method [30]. 
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The plasmid pCMV3-2019-nCoV-Spike (S1+S2)-long encodes full-length spike from SARS-
CoV-2 amino acid 1–1273 (GenBank accession number YP_009724390 /QHD43416.1) was 
obtained from Sino Biological (catalogue number VG40589-UT).  This contained codon 
optimised cDNA for expression of the protein in mammalian cells inserted into the KpnI/XbaI 
sites of the mammalian expression vector pCMV3-untagged under control of the high-level 
expression mammalian human enhanced cytomegalovirus (CMV) immediate early promoter. 
 
Transient Expi293F™ transfection 
Secretion levels from plasmid DNA constructs were evaluated following transient 
transfections of Expi293F™ cells using the ExpiFectamine™ 293 Transfection kit (Gibco, 
LifeTechnologies).  Briefly, Expi293F™ cells in suspension (100 mL, 2x106/mL) were 
transfected with 100µg DNA and conditioned medium harvested at day 6 post-transfection.  
Conditioned supernatant was filtered through 0.22 µm bottle top filters (Merck Millipore) and 
sodium azide added to a final concentration of 0.2% (w/v). Cell pellets were stored at -80°C.  
Cell lysates (intracellular RBD and N protein) were generated by processing the cell pellets 
in a suitable volume of RIPA buffer (Sigma Aldrich R0278) according to the manufacturer’s 
recommendations. 
 
Sandwich ELISA for detection of secreted and intracellular RBD and N protein 
Commercial kits/antibody pairs were used in both cases.  N protein was detected using the 
SARS-CoV-2 NP ELISA kit from Bioss, (cat# BSKV0001) according to the supplier’s 
instructions.  Quantitation relied on the standard curve generated using the NP standard 
supplied with the kit.  RBD was detected using a sandwich ELISA consisting of a capture 
antibody (SARS-CoV-2 S neutralising mouse monoclonal antibody (mAb) Sino Biological, 
40591-MM43) combined with an HRPO-labelled detection antibody from the SARS-CoV-2 
spike RBD Antibody Pair (Epigentek A73682).  Capture antibody was coated at 200 ng/well 
and detection antibody was used at a dilution of 1:1000.  
 
Peptides and proteins 
Peptides were selected based on immune epitope database (IEDB) (http://www.iedb.org/) 
binding predictions [31] and from reports in the literature.  Peptides (Table S1) were 
synthesised at >90% purity (GenScript), stored lyophilised at -80°C and then reconstituted in 
phosphate buffered saline (PBS) on day of use.  SARS-CoV-2 RBD and N protein peptide 
pools were purchased from JPT Peptide Technologies and GenScript, respectively.  SARS-
CoV-2 N and S1 proteins were obtained from Genscript and Sino Biological. 
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Animals and immunisation protocol 
Animal experiments were carried out with ethical approval under a UK Home Office-
approved Project License. HLA-A2.1+/+ HLADP4+/+ hCD4+/+ (HHDII/DP4; EM:02221, 
European Mouse Mutant Archive), HLA-A2/DR1 (HHDII/DR1; Pasteur Institute), HLA-A2 
(HHDII; Pasteur Institute) transgenic mice or BALB/c and C57Bl/6 (Charles River) aged 7–12 
weeks were used. 
Mice were immunised with 1 µg plasmid DNA, coated onto gold particles, intradermally using 
a HeliosTM gene gun (BioRad, Hemel Hempstead, UK) on days 1, 8 and 15 and responses 
analysed on day 21, unless stated otherwise. 
 
ELISpot assays 
Murine ELISpot kits (Mabtech) were used with 5x105 splenocytes/well in RPMI with L-
glutamine, 10% (v/v) foetal bovine serum (FCS) supplemented with penicillin, streptomycin, 
HEPES and 10-5M 2-β mercaptoethanol (Invitrogen). Synthetic peptide (5 μg/mL) or peptide 
pool (1 ug/mL) were added to triplicate wells.  CD8, or CD4  mAbs were added for blocking 
studies (20 μg/mL).  Plates were incubated at 37°C for 40 hours in an atmosphere of 5% 
(v/v) CO2.  Spots were counted using an automated plate reader (Cellular Technologies Ltd). 
 
Intracellular cytokine analysis 
Splenocytes (5x106/mL) were incubated with 5 µg/mL synthetic peptide or 0.5 µg/mL whole 
recombinant protein for 7 days.  Cells were washed, plated at 5x106/ml and stimulated for 8–
12 hr with medium alone, 0.25 μg/mL CD3 mAb (Thermofisher) as a positive control, 5 μg/ml 
synthetic peptide or 1 μg/mL peptide pool. Cells were incubated at 37°C for 8 hr with 
Brefeldin A (BD Biosciences) and Monensin (Thermofisher) being added for the last 7 hr of 
incubation.  After 8 hr incubation, cells were held at 4°C until staining.  Cells were then 
washed and stained with APC efluor780 conjugated anti-mouse CD4 and ViogreenTM 
conjugated anti-mouse CD8 mAbs.  Cells were subsequently washed, fixed and 
permeabilised using intracellular fixation/permeabilisation buffers (ThermoFisher).  
Intracellular antibody staining was performed in permeabilisation buffer for 30 min before 
washing and fixing.  Stained samples were analysed using a Milteny Biotech MACSQuantTM 
10 flow cytometer.  Full details of the mAbs used are provided in Table S2. 
 
ELISA for N and S1 specific antibodies 
Blood collected from mice was allowed to clot for at least 30 min at room temperature, 
centrifuged at 1000g for 10 min and serum collected.  Serum from naïve mice was used as a 
control.  Sera were diluted in 2% (w/v) bovine serum albumin in PBS (BSA-PBS) and 
incubated for 1 hr at room temperature (RT) in coated (S1 antigen, GenScript #Z03501 or 
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Sino Biological and N-protein, GenScript #Z03488, both at 200 ng/well) and blocked ELISA 
plates.  Antibody binding to S1 antigen was detected using a three-step approach consisting 
of anti-mouse Fc biotin (Sigma Aldrich B7401) followed by streptavidin-HRPO (Life 
Technologies SA1007) and finally TMB (3,3´, 5, 5´- tetramethylbenzidine) Core+ reagent 
(Bio-Rad BUF062C) for development.  Antibody binding to N protein was detected using 
conventional two-step ELISA with an HRPO-conjugated anti-mouse Fc antibody (Sigma 
Aldrich A9309).  All assays included a standard curve of mouse neutralising S1 antibody and 
mouse anti-N antibody (Sino Biological).  Standard curves were used to extrapolate the 
amount (µg/mL) of specific immunoglobulin (Ig) in the sera samples. 
 
Pseudotype neutralisation assay 
SARS-CoV-2 S protein plasmids were generated and cloned, and pseudoparticles 
generated as previously described [32, 33].  Briefly, 1.5 × 106 HEK293T cells were seeded 
overnight in a 10 cm diameter Primaria-coated dish (Corning).  Transfections were 
performed with 2 µg each of the murine leukemia virus (MLV) Gag-Pol packaging vector 
(phCMV-5349), luciferase encoding reporter plasmid (pTG126) and plasmid encoding 
Wuhan strain SARS-CoV-2 spike using 24 µL polyethylenimine (Polysciences) in Optimem 
(Gibco).  Reaction mixtures were replaced with Complete DMEM after 6 hr.  A no-envelope 
control (empty pseudotype) was used as a negative control in all experiments. Supernatants 
containing SARS-CoV-2 pseudotype viruses (pv) were harvested at 72 hr post-transfection 
and filtered through 0.45 μm membranes.  Pseudotypes generated in the absence of the 
spike were used as a negative control.  For infectivity and neutralisation testing of SARS-
CoV-2 pseudoparticles, 1 × 105 VeroE6 cells were seeded on white 96-well tissue culture 
plates (Corning) and incubated overnight at 37°C.  The following day, SARS-CoV-2 
pseudotypes were mixed with appropriate amounts of heat inactivated serially diluted sera 
and then incubated for 1hr at RT before adding to cells.  After 72 hrs at 37°C, cells were 
lysed with cell lysis buffer (cat no. E1500; Promega) and placed on a rocker for 15 min.  
Luciferase activity was then measured in relative light units (RLUs) using a FLUOstar 
Omega plate reader (BMG Labtech) and MARSdata analysis software.  Each sample was 
tested in triplicate.  Neutralising activities were reported as reciprocal serum dilution levels 
corresponding to 50% inhibitory dilution (ID50) values and were calculated by nonlinear 
regression (GraphPad Prism version 9.1.2), using lower and upper bounds (0% and 100% 
inhibition) as constraints to assist curve fitting. 
 
Live virus neutralisation assay 
SARS-CoV-2 infectious virus (CVR-GLA-1) was obtained from the National was obtained 
from the Centre For AIDS Reagents, NIBSC, UK. 
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Live virus neutralisation assays were performed using method previously described [34], 
except that 790 TCID50/ml of the SARS-CoV-2 virus was added to each serum dilution.  
Additionally, for some experiments, the sera were diluted down to 1:81,920. 
 
ACE2 binding inhibition assay 
A V-PLEX COVID-19 ACE2 neutralisation kit from Meso Scale Diagnostics LLC was used to 
investigate the ability of vaccine-elicited antibodies to block the binding of ACE2 to RBD or 
whole S proteins.  V-plex SARS-CoV-2 Panel 7 multispot plates containing S1 RBD and 
whole S proteins from Lineage A (originally identified in Wuhan) and variant (B1.1.7/Alpha, 
B1.351/Beta, P.1/Gamma) SARS-CoV-2 strains were blocked, followed by incubation with 
sera at 1:100 dilution and Sulfo-tagged human ACE2 protein, according to the 
manufacturer’s instructions.  Results are expressed as percentage inhibition of ACE2 




Statistical analysis was performed using GraphPad Prism software version 9.  Comparative 
analysis of the ELISpot results was performed by applying paired or unpaired ANOVA as 
appropriate with Sidak’s multiple comparisons test and P values calculated accordingly.  
P<0.05 values were considered statistically significant. 
 
Results 
Design and characterisation of DNA constructs 
Spike RBD and N protein DNA sequences were obtained from the Lineage A SARS-CoV-2 
variant and engineered alongside N terminal human IgH leader sequences into the pVAX1 
vector backbone.  Short (aa330-525) or long (aa319-541) S protein RBD sequences were 
fused in frame with human IgG1 Fc constant region, a fibritin timer domain or disulphide 
bridge motif (Figure 1A).  N protein sequences were added alongside the S protein RBD 
sequences, alone or fused in frame with human IgG1 Fc (Fc) constant region or a modified 
human IgG1 Fc (Fc iV1) constant region (Figure 1A). 
 
Expression of both N protein and RBD from DNA constructs was assessed by transfection of 
Expi293FTM cells followed by analysis of supernatant and cell lysate samples by sandwich 
ELISA.  Constructs expressing the RBD region as a monomer or linked to Fc showed the 
highest levels of RBD protein secretion by Expi293FTMcells, whereas those containing the 
long RBD trimer or shorter RBD trimer versions exhibited lower protein secretion levels 
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(Figure 1Bi).  No significant difference was seen between the trimer variants (Supplementary 
Figure 1).  The N protein secretion levels were overall much lower than the RBD secretion, 
with the N protein producing more secreted protein than the Fc and Fc iV1 N protein 
constructs (Figure 1Bii).  Unlike antibody responses, the stimulation of a T cell response is 
not reliant on secreted protein, because of which protein was also measured in cell lysates 
to determine if protein was made but not secreted.  Cells transfected with the construct 
expressing the RBD monomer showed the highest level of RBD protein in the cell lysates 
(Figure 1Ci). A similar observation was seen for the N protein with highest levels in the cell 
lysate transfected with the construct expressing the non-fused N protein (Figure 1Cii).  
Collectively, the results suggest that functional RBD and N protein are produced as both 
secreted and intracellular forms, which can stimulate both T-cell and antibody responses. 
 
Linkage of N protein to modified Fc stimulates superior N specific T cell responses 
T cell responses in mice following immunisations with vaccine constructs containing the N 
monomer, monomer linked to Fc or modified Fc (iV1) were evaluated using RBD and N 
protein overlapping peptide pools.  Peptide pools contain 15aa peptides that overlap by 
11aa and span the entire sequence and stimulate both CD4 and CD8 T cell responses 
without requiring any prior knowledge of the presenting MHC allele.  Splenocytes were 
isolated from mice 7 days after the last immunisation and T cell responses were assessed 
ex vivo by IFNγ ELISpot following stimulation.  In addition to the peptide pools, several 
peptides were selected from published reports and using prediction algorithms that were 
known or suggested to bind to HLA-A2 or murine H-2Kb/d, H-2Db/d, I-Ab or I-Ad/Ed (Table 
S1).  
A high frequency of T cells specific to the N protein was detected in mice immunised with 
DNA constructs containing the N protein linked to modified Fc (iV1) when compared to 
constructs containing N protein (p=0.0278) or the N protein linked to unmodified Fc (Figure 
2Ai).  A high frequency of T cells recognising the N 138-146 peptide was induced in HLA-A2 
transgenic mice following immunisation with the DNA construct containing the N protein 
linked to a modified Fc (iV1) when compared to the frequency observed in mice immunised 
with the constructs containing N protein alone (p=0.0150) or linked to Fc (p=0.0161) (Figure 
2Aii).  One peptide, conserved between SARS-CoV and SARS-CoV-2 [35], stimulated a 
response in cells from immunised HLA-A2 transgenic mice (N 138–146), thereby highlighting 
the potential of these T cells to recognise other coronaviruses. 
A high frequency of T cells specific to the RBD antigen was detected in mice immunised with 
the vaccine constructs.  The construct containing the RBD monomer induced a higher 
frequency of T cells specific for the RBD protein when compared to the frequency of 
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responses induced by a DNA construct containing the whole S protein (p=0.0002) (Figure 
2B). 
 
T-cell responses were further evaluated in BALB/c, C57Bl/6 and HLA-A2 transgenic mice 
following immunisation with the DNA construct expressing RBD alongside N linked to 
modified Fc (iV1) (also known as SN15) using RBD and N peptide pools and individual 
peptides.  A high frequency of T cells specific for SARS-CoV-2 N and RBD were detected in 
all strains of mice.  T cell responses to two longer peptides (RBD 505–524 and N 80–100) in 
addition to the RBD and N peptide pools were seen in BALB/c mice (p=0.0012, p=0.0171, 
p=0.0001 and p=0.0368, respectively) (Figure 3A). Immunised C57Bl/6 mice also exhibited T 
cell responses to the RBD 505–524 peptide and lower frequency responses, that did not 
reach significance to the N 212–231 and N 101–121 peptides (Figure 3B).  T cell responses 
to the two short peptides RBD 417-425 (p<0.0001) and N 138-146 (p<0.0001) peptides were 
detected in immunised HLA-A2 transgenic mice (Figure 3C), these peptides have been 
described as potential HLA-A2 epitopes in human studies [35, 36].  To confirm these to be 
CD8 peptides, the T cell responses were assessed in the presence of CD4 or CD8 blocking 
antibodies (Figure 3D).  The presence of the CD8 blocking antibody totally abrogated both 
responses (p<0.0001) whereas the CD4 blocking antibody had little effect, thus confirming 
that these were CD8 responses in HLA-A2 transgenic mice. 
 
To characterise the T cell responses to the longer peptides which have the potential to 
contain both CD8 and CD4 epitopes, BALB/c mice were immunised with DNA constructs 
expressing RBD alongside N linked to modified Fc (iV1) and T cell responses to the N 80-
100 and RBD 505-524 peptides monitored by IFNγ ELISpot assay in the presence of CD4 or 
CD8 blocking antibodies.  A strong T cell response to the N 80-100 peptide was observed 
and this was efficiently blocked by the CD4 antibody (p=0.0009) but not the CD8 antibody, 
implying the presence of a CD4 epitope within this peptide sequence (Figure 3Eii).  Although 
a strong T cell response to the RBD 505–524 peptide was observed this was not significantly 
inhibited by either the CD4 or CD8 blocking antibodies, suggesting that this peptide 
sequence stimulates both CD4 and CD8 responses (Figure 3Ei). 
 
The T cell responses to the RBD and N peptide pools were examined by intracellular 
cytokine staining using splenocytes from BALB/c and C57Bl/6 mice immunised with the DNA 
construct expressing RBD alongside N linked to modified Fc (iV1).  This enabled both the 
confirmation of CD4 or CD8 mediated responses as well as analysis of the cytokine profile of 
the responses.  To determine the presence of CD4 T cell responses to the vaccine, 
splenocytes from immunised BALB/c mice expanded in vitro with recombinant S1 and N 
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protein were restimulated with either RBD or N peptide pools and analysed for expression of 
IFNγ, TNFα and IL10.  A population of CD4 positive and CD4 negative T cells produced 
IFNγ and TNFα in response to restimulation with the RBD peptide pool (Figure 4A) 
suggesting the likely presence of both CD4 and potentially CD8 responses specific to RBD.  
Only CD4 positive T cells produced IFNγ and TNFα in response to stimulation with the N 
peptide pool.  No cytokines were produced by the CD4 negative T cells suggesting CD4 
responses to the N protein which is consistent with the ELISpot data (Figure 4A).  There was 
no evidence of any IL-10 responses. 
Responses of splenocytes from the BALB/c mice in the ELISpot and intracellular cytokine 
analysis to the RBD peptide pool and the RBD 505–524 peptide were anticipated to be both 
CD4 and CD8 mediated.  To confirm this, splenocytes from immunised BALB/c mice were 
expanded in vitro with RBD 505–524 peptide and examined by intracellular cytokine staining.  
The response to the RBD 505–524 peptide was predominantly CD8 cells making both IFNγ 
and TNFα but no IL-10 (Figure 4B).  However, a small response in the CD4 population was 
also observed thus providing evidence that this peptide contains both CD4 and CD8 
epitopes and confirming both CD4 and CD8 RBD specific responses are generated by this 
vaccine construct. 
 
In addition to the responses in the BALB/c model, responses to the N and RBD proteins 
were further characterised in C57Bl/6 mice.  For this, splenocytes from immunised C57Bl/6 
mice were also expanded in vitro with S1 or N proteins and analysed for specific responses 
by intracellular cytokine staining.  Figure 4C shows IFNγ and TNFα responses to the N 
peptide pool among both CD4 and CD8 T-cell populations.  No evidence of IL-10 or IL-4 
responses was observed indicating that the CD4 cells exhibited a Th1 phenotype. Low 
frequency CD4 and CD8 responses were also stimulated using the N 101–121 peptide in 
this model (Figure 4C).  Analysis of splenocytes from C57Bl/6 vaccinated mice also 
demonstrate an expansion of both CD4 and CD8 T cells that respond to the RBD 505–524 
peptide.  These responses display an IFNγ and TNFα phenotype, with no evidence of IL-10 
or IL-4 responses (Figure 4C).  These data provide further evidence in a second HLA mouse 
model that CD4 and CD8 T cell responses can be stimulated by vaccination to both the N 
and RBD proteins. 
 
DNA vaccination stimulates strong anti-N and anti-RBD binding antibody responses that 
show efficient pseudotype neutralisation 
Humoral responses were evaluated in sera from immunised BALB/c mice immunised with 
constructs containing the RBD monomer, whole S, trimer or monomer linked to Fc and 
analysed for reactivity to SARS-CoV-2 S1 protein by ELISA.  (Figure 5Ai and ii).  Vaccination 
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induced potent antibody responses to the S1 protein which were detectable in sera from all 
constructs at up to 1 in 100,000 dilution. Constructs containing the RBD monomer and RBD 
linked to Fc showed the highest EC50 and quantity of Ig with approximately 50 µg/mL anti-S1 
Ig being detected. 
The generation of a potent antibody response capable of inhibiting the binding of the S 
protein to ACE2 receptor and subsequent viral infection is vital for an effective SARS-CoV-2 
vaccine.  The ability of sera from mice immunised with the DNA constructs containing RBD 
monomer, trimer or monomer linked to Fc to prevent viral infection was therefore tested in a 
pseudotype neutralisation assay.  For this, sera from mice immunised with the RBD 
monomer showed higher neutralisation IC50 values (Figure 5Bi-ii) with 50% neutralisation at 
serum dilutions of greater than 1in 5000, higher than that seen with the NIBSC 20/136 
international antibody standard.  Sera from mice immunised with the RBD monomer DNA 
construct showed higher IC50 neutralisation values compared to that from mice immunised 
with the DNA expressing the whole S (Figure 5C).  This is also evident from the differing 
antibody levels shown in Figure 5Aii where the RBD monomer generated high EC50 values 
when compared to the construct expressing full-length S antigen. 
 
Sera were also analysed for reactivity to SARS-CoV-2 N protein by ELISA. Lower antibody 
responses were seen to the N protein than to the RD, with similar EC50 values obtained for 
all constructs irrespective of whether the N protein was fused to Fc or not (Figure 5D). 
 
Responses induced by DNA vaccination show variant cross reactivity 
Emerging SARS-CoV-2 variants are a major cause for concern as they have the potential for 
greater infectivity and increased disease severity.  As variants of SARS-CoV-2 have the 
potential to impact the efficacy of the current vaccines approved for emergency use that 
were generated using the original Lineage A virus, there remains doubt about the 
effectiveness of current vaccines based on this isolate against these new variants.  We 
therefore examined the ability of sera from BALB/c mice immunised with the DNA vaccine 
expressing RBD alongside N linked to modified Fc (iV1) (also known as SN15) for reactivity 
to the Lineage A SARS-CoV-2 S1 protein as well S1 proteins incorporating the mutations 
seen in the B.1.1.7 (Alpha) and B.1.351 (Beta) variants by ELISA.  Vaccination induced a 
potent antibody response with reactivity to all the S1 proteins detectable in sera at up to a 1 
in 100,000 dilution (Figure 6A).  However, in line with other reports, we also observed a 
significant (p<0.0001) reduction in reactivity to the B.1.351 (Beta) variant S1 protein 
compared to the Lineage A protein, whereas reactivity to the B.1.1.7 (Alpha) variant S1 
protein was not significantly reduced. 
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One of the most concerning variants of concern (VoC) currently in circulation is B.1.351 
(Beta).  Recent data have suggested that although the approved vaccines induce responses 
that can provide some cross-reactivity with the B.1.1.7 (Alpha) variant, they are less effective 
against the B.1.351 (Beta) and P.1 (Gamma) variants [37-39].  To address this, we 
engineered a new construct encoding the RBD protein containing the mutations within the 
B.1.351 (Beta) variant alongside N linked to modified Fc (iV1) (also known as SN17).  Sera 
from mice immunised with the original DNA vaccine construct, the B.1.351 (Beta) vaccine 
construct or the construct expressing the whole S antigen from the original variant were 
analysed for reactivity to the original Lineage A SARS-CoV-2 S1 protein as well S1 protein 
incorporating the mutations seen in the B.1.351 (Beta) variant by ELISA.  Substantial 
antibody responses were observed to the protein variants up to 1 in 100,000 dilution (Figure 
6B).  As noted above, sera raised against the original Lineage A vaccine exhibited a 
decrease in reactivity to the B.1.351 (Beta) variant S1 protein compared to the Lineage A S1 
protein with the EC50 decreasing from 4664 to 2949.  The responses induced by the B.1.351 
(Beta) variant vaccine generated higher titres to the B.1.351 (Beta) variant S1 protein (EC50 
of 3931) with lower titres against the original Lineage A S1 protein (EC50 of 2086).  The 
variant vaccines induced higher titres to both the original Lineage A S1 and B.1.351 (Beta) 
S1 proteins compared to responses induced by the whole S DNA vaccine (EC50 of 1389 and 
644 respectively).  The sera were also assessed in a similar antibody binding assay on the 
MesoScale Discovery platform that includes the whole spike and RBD proteins from original 
Lineage A, B.1.351 (Beta), B.1.1.7 (Alpha) and P.1 (Gamma) variants (Supplementary 
Figure 2) where the same pattern of responses was observed.  Sera from immunised mice 
showed similar reactivity to either the original Lineage A and B.1.1.7 (Alpha) variants or the 
B.1.351 (Beta) and P.1 (Gamma) variants, as might be expected based on their RBD 
mutations.  Interestingly, the sera from mice vaccinated with the original Lineage A vaccine 
and the B.1.351 (Beta) variant vaccine showed similar titres of antibodies recognising the 
Lineage A N protein and a N protein variant containing the D3L, R203K, G204R and S235F 
mutations, two of which are also found in the B.1.1.7 (Alpha) variant (Supplementary Figure 
3), suggesting perhaps that N protein specific antibodies may be more cross-reactive or bind 
to conserved regions of the N protein. 
 
The ability of sera from immunised mice to inhibit the binding of the ACE2 receptor to the 
variant RBD or whole S proteins was assessed using the MesoScale Discovery platform.  
Inhibition of RBD binding to ACE2 was higher for sera from mice vaccinated with the original 
Lineage A vaccine construct and the B.1.351 (Beta) variant vaccine construct compared to 
that seen with the NIBSC 20/136 control (Figure 6Ci).  In contrast, sera from mice 
immunised with whole S DNA showed a lower capacity to inhibit ACE2 binding which was 
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similar to that of the NIBSC 20/136 control.  Sera from mice immunised with the original 
Lineage A vaccine construct inhibited 80–100% of ACE2 binding to the original Lineage A 
RBD and B.1.1.7 (Alpha) variants with a drop to 50–60% against the B.1.351 (Beta) and P.1 
(Gamma) RBD variants.  The reverse is seen in sera from mice immunised with the B.1.351 
(Beta) variant vaccine.  Despite a reduction in the inhibition of ACE2 binding to the B.1.351 
(Beta) and P.1 (Gamma) RBD variants, the inhibition levels remain above those seen using 
sera from whole S DNA immunised mice. A similar trend is seen in the ACE2 receptor 
binding inhibition assay with the variant whole S proteins (Figure 6Cii). 
 
Sera from mice immunised with the original Lineage A or B.1.351 (Beta) variant vaccines 
were also assessed in pseudotype and live virus neutralisation tests against the original 
Lineage A and B.1.351 (Beta) variants.  Sera from mice immunised with the original variant 
vaccine showed potent neutralisation of the original Lineage A pseudotype, with reduced 
efficacy against the B.1.351 (Beta) variant vaccine (ID50 values of 6232 and 2137 
respectively) (Figure 6D).  Sera from mice immunised with either vaccine showed 
neutralisation of the B.1.351 (Beta) pseudotype variant, but little difference was noted (ID50 
values of 948 and 997, respectively).  In the live virus neutralisation assay sera from mice 
immunised with either the original Lineage A or the B.1.351 (Beta) variant vaccines 
neutralised of the original Lineage A virus with ID50 values of 4964 and 1334 respectively 
and both are better than NIBSC controls (Figure 6E). 
 
In contrast to the antibody responses, the T cell responses did not seem to be impacted by 
variations between the virus strains (Figure 6F).  Splenocytes from mice immunised with 
either the original Lineage A vaccine or the B.1.351 (Beta) vaccine were stimulated ex vivo 
with RBD and N peptide pools derived from the original sequence.  T cell responses specific 
for RBD and N were detected with little difference between the response induced by the 
different vaccine constructs.  These results suggest that mutations in the B.1.351 (Beta) 
variant have less impact on the T cell responses. 
 
Discussion 
We describe the development of a DNA vectored vaccine targeting both S and N proteins of 
SARS-CoV-2.  In this study, we have demonstrated that the vaccine induces CD4 and CD8 
T cell responses to both N and RBD proteins in addition to eliciting potent neutralising 
antibody responses.  We have shown the stimulation of N and RBD peptide specific T cell 
responses in several mouse strains, demonstrating that peptides derived from N and RBD 
can be presented via various HLA alleles, thereby indicating the broad application of this 
vaccine in populations possessing a diverse range of HLA alleles.  In responding immunised 
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mice T cells released IFNγ and TNFα upon stimulation in vitro, two Th1 cytokines required to 
induce potent immune responses, with the absence of IL-10 and IL-4 that could potentially 
induce damaging Th2 responses.  Strong T cell immune responses were induced by 
vaccines based on the original Lineage A SARS-CoV-2 isolate and the B.1.351 (Beta) 
variant, suggesting that the mutations may not be as significant for evading T cell responses 
as they are for antibody responses.  These data support the recent report from Tarke et al. 
suggesting SARS-CoV-2 variants have little impact on the T cell responses induced [40].  A 
strong T cell response is not only essential for the generation of humoral immunity in 
coronavirus infection [41] but has also been shown to persist over time and is therefore likely 
to be important for long term protection [22, 42].  Grifoni et al. have indeed shown the 
importance of both T cell and humoral immunity to S and N proteins for SARS-CoV-2 
protection [16].  Evidence from SARS-CoV demonstrates the persistence of T cell responses 
to both S and N proteins up to 11 years post infection [42].  In addition, studies in mouse 
models of SARS-CoV have shown that memory CD8 T cells provide efficient protection from 
SARS-CoV infection [43].  Therefore, to be most effective, immunity stimulated by 
vaccination will likely need to comprise of both potent virus-specific CD8 and CD4 T cell 
responses as well as neutralising antibody responses.  Several reports using murine models 
indicate that a strong Th1 response alongside virus specific CD8 response and virus specific 
neutralising antibodies are necessary for successful control of SARS-CoV and MERS [44, 
45].  Although it is too early to determine the full extent of longevity of the T-cell responses 
for SARS-CoV-2 in humans, infection-specific memory T cells have been detected in 
convalescent patients and responses can be detected up to 18 weeks after infection.  
Interestingly the responses to S antigen in convalescent patients appear superior to those 
detected in individuals vaccinated with the current approved vaccines [46] which is 
consistent with our unpublished data analysing responses to SARS-CoV-2 in humans.  
Studies by Ferretti et al. and Peng et al. reveal that SARS-CoV-2 reactive memory T cells in 
convalescent patients were more prevalent to antigens that are not subject to mutational 
variation such as the N protein [47, 48].  In further support of these data, the study by Le 
Bert et al demonstrated that N protein specific T cell responses in patients who were infected 
with SARS-Co-V were more likely to cross react with homologous SARS-CoV-2 peptides 
than those from NSP7 and NSP13 [22].  This supports the rationale for targeting of both S 
and N proteins in vaccine design such as the strategy described in this study to induce both 
T cell and antibody mediated immunity. 
 
Herein, we have achieved simultaneous production of strong neutralising antibody titres as 
well as potent CD8 and CD4 T cell responses to epitopes from both SARS-CoV-2 S and N 
proteins.  The RBD monomer elicited the strongest neutralising antibody responses with ID50 
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titres of >5000.  In this study, these titres were higher than those elicited by a DNA vaccine 
encoding whole S protein, which was also reflected in the ACE2 binding inhibition assay, 
suggesting that vaccination with RBD may elicit higher neutralising antibody titres than 
vaccination with the complete S antigen.  These data compare favourably with other studies 
in which the whole S protein or an RBD trimer have been used to produce vaccine 
candidates that generate potent neutralising antibodies [23, 49-52].  Indeed, it has been 
demonstrated that the majority of the neutralising antibodies to S protein target the RBD, 
supporting the inclusion of just the RBD sequence in this bivalent vaccine [53]. 
 
In addition to strong RBD specific antibody responses the induction of antibody responses to 
the N protein were also detected.  Although, these are likely to be non-neutralising 
antibodies, they often have the ability to clear viral infections [54-56].  Additionally, recent 
reports using lymphocytic choriomeningitis virus (LCMV) as a model virus suggest an 
alternative mechanism for the beneficial effect of N protein specific antibodies which involves 
the stimulation of antibody-dependent intracellular neutralisation and promotion of N specific 
cytotoxic T lymphocytes (CTLs) that efficiently clear virus infected cells [57].  The study by 
Caddy et al. suggests that N-specific antibodies can bind N protein either released during 
viral lysis or expressed on the surface of infected cells and that the immune complex can be 
taken up by APCs, in which TRIM21 targets N protein for cytosolic degradation and the 
generation of cytotoxic T cells against N peptides.  This is a rapid response and mediates 
viral clearance prior to the establishment of neutralising antibodies.  In support of this 
hypothesis the vaccine construct containing N protein fused to the modified Fc sequence 
induced significantly better T-cell responses to N protein and also elicited higher responses 
to RBD than a similar construct expressing the same RBD construct but with unmodified Fc 
linked to N (data not shown).  This suggests that the modified N-Fc fusion is acting as an 
adjuvant and activating APCs to also enhance the T-cell response to other antigens.  It is 
therefore possible that SARS-CoV-2 N specific antibodies could play a role in viral clearance 
and protection.  A recent report by Matchett et al. has demonstrated the protective ability of 
an adenovirus type-5 (Ad5)-vectored vaccine encoding N protein from SARS-CoV-2 in 
murine and hamster infection models and shows that protection is associated with the rapid 
stimulation of N protein specific T cell responses [58], thereby providing further evidence for 
the important role of N protein specific T cell responses.  However, any evidence of N 
protein specific antibody response was not described.  Reports by Rice et al and Seiling et al 
have also demonstrated the benefit of combining both S and N proteins as vaccine targets 
using a Ad5 vectored delivery platform [23, 59].  This delivers a modified S protein to 
promote surface expression and a modified N protein to enhance MHCI and II presentation, 
resulting in the generation of both N and S specific T cell and neutralising antibody 
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responses in preclinical studies [23].  In humans, T cell responses generated from a single 
dose of vaccine are of similar frequency to those seen in previously infected patients, 
although no data on antibody responses are reported [59]. 
 
The emergence of new SARS-CoV-2 variants has highlighted the importance of generating a 
vaccine mediated response that is effective against the variants as well as the original strain.  
Mutations in the S protein have been shown to reduce the recognition by antibodies, thereby 
allowing the virus to escape antibody neutralising effects and increase the transmissibility, 
infection rate and disease severity [19, 20, 60, 61].  Current vaccines approved for 
emergency use only encode the original Lineage A S protein sequence and have shown 
varying levels of cross-reactivity against the variant S proteins with most reporting a drop in 
recognition and neutralisation efficacy, particularly against the B.1.351 (Beta) variant [53, 62, 
63].  In other reports, higher cross-reactivity is retained against the B.1.1.7 (Alpha) variant 
that has fewer significant mutations within the RBD sequence [61, 64].  B.1.1.7 (Alpha) 
variant contains only an asparagine (N) to tyrosine (Y) at position 501 within the RBD 
sequence whereas B.1.351 (Beta) variant contains this same N501Y mutation as well as two 
further mutations; lysine (K) at position 417 to asparagine (N), glutamic acid (E) at position 
484 to lysine (K).  The P.1 (Gamma) variant contains similar mutations within the RBD 
sequence (summarised in Supplementary Table 3). In our studies we have demonstrated a 
decrease in antibody titres and ACE2 binding inhibition against the B.1.351 (Beta) variant 
and P.1 (Gamma) variant S proteins in sera from mice immunised with the DNA vaccine 
encoding the original Lineage A RBD sequence.  However, these responses remain superior 
to those seen in the sera from mice immunised with whole S encoding DNA.  Encouragingly, 
these antibody responses showed a similar binding titre in ELISA and ACE2 binding 
inhibition with the B.1.1.7 (Alpha) variant S protein suggesting that mutations in the B.1.1.7 
(Alpha)variant S protein do not reduce the antibody response induced by the DNA vaccine 
encoding the original Lineage A RBD sequence. 
 
We have also demonstrated the efficacy of a vaccine construct encoding the B.1.351 (Beta) 
variant RBD sequence and show high titre antibody responses to the B.1.351 (Beta) variant 
S protein that also cross react with the original Lineage A S protein.  Recent reports in the 
literature suggest that sera from patients with the B.1.351 (Beta) variant of SARS-CoV-2 
have high titre cross neutralising antibodies that also recognise the original SARS-CoV-2 
virus [65].  In this report we demonstrate that although sera from mice immunised with the 
vaccine encoding the B.1.351 (Beta) variant RBD show a reduction in ACE2 binding 
inhibition of the Lineage A and B.1.1.7 (Alpha) variants, responses remain similar to those in 
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sera from whole S DNA immunised mice and remain above 50% inhibition against all 
variants tested. 
 
Interestingly, in pseudotype and live virus neutralisation assays there is less difference 
between the sera from the original Lineage A and B.1.351 (Beta) vaccinated mice with 
strong neutralisation of the Lineage A variant from mice immunised with either vaccine 
showing ID50 titres of >1000.  It is possible that this reflects a polyclonal antibody response 
against both S and N proteins.  Although a decrease in neutralisation of the B.1.351 (Beta) 
variant is seen for both vaccines, neutralisation titres are consistent with the current vaccines 
targeting S protein only [53, 66].  Despite this, these data imply that there is evidence of 
cross-reactivity and use of a vaccine encoding the B.1.351 (Beta) variant sequences may 
provide additional protection against multiple SARS-CoV-2 variants. 
 
In summary, DNA provides a cost effective and rapid to manufacture product that can be 
easily adapted to encode sequences or mutations present in new variants.  DNA vectors 
also lend themselves well to use in multiple homologous prime boost immunisation regimes, 
which is often not compatible with other viral vector-based vaccination strategies due to 
limitations of anti-vector immunity but may be vital to combat rapidly emerging virus variants.  
Data from our cancer vaccine platform demonstrates the stability of the DNA vector used in 
this study and its safety in human subjects [27]. The bivalent DNA SARS-CoV-2 vaccine 
stimulates strong humoral and cellular immunity that can be easily adapted to emerging virus 
variants.  Furthermore, the responses elicited by both original Lineage A and B.1.351 (Beta) 
variant vaccines show cross-reactivity with multiple viral variants and support the potential 
clinical application of these vaccines. 
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Figure 1.  Schematic representation of the DNA SARS-CoV-2 plasmids and expression of N 
and RBD proteins.  A, DNA constructs expressing N and RBD variants (i)-(ix). Spike RBD 
and NP variant chains are within expression cassettes 1 and 2 of the pVaxDC vector.  
Numbers indicate amino acids. SP: signal peptide/ Human IgH Leader, RBD: receptor-
binding domain, Fd: Fibritin fold on trimer motif from T4 bacteriophage 
(GYIPEAPRDGQAYVRKDGEWVLLSTFL). DBM: Disulphide bridge motif. Both fibritin fold 
on and disulphide bridge motif are attached to the S RBD via glycine/serine linkers. In some 
constructs the Spike RBD domain and N protein is fused inframe with HuigG1 FC or the 
improved modified version of the constant domain, designated iV1. 
RBD (i) and N (ii) protein expression from transfected Expi293TM cells in the supernatant (B) 
and cell lysate (C). 
 
Figure 2.  Linkage of N protein to modified Fc stimulates superior N and RBD specific T cell 
responses.  A, BALB/c, C57Bl/6 or HLA-A2 transgenic mice immunised with DNA constructs 
expressing N, N linked to Fc or N linked to modified Fc (iV1) and T cell responses monitored 
by IFNγ ELISpot assay to N peptide pool (i) or N 138-146 peptide (ii).  B, Assessment of 
RBD specific T cell responses in HLA-A2 transgenic mice using RBD peptide pool (i) or RBD 
417-425 peptide (ii) from constructs containing RBD alongside N, N linked to Fc or N linked 
to modified Fc (iV1).  C, Assessment of RBD specific T cell responses using RBD peptide 
pool (i and iii) or RBD 417-425 peptide (ii) from constructs containing RBD variants 
alongside N linked to modified Fc (iV1) (i and ii) or RBD monomer alongside N linked to 
modified Fc (iV1) compared to DNA encoding the whole S protein (iii).  Responses are 
measured as spots/106 splenocytes.  Symbols represent mean response for individual mice, 
line represents mean value between mice. Significant P values are shown from studies with 
matched data points, Data is collated from multiple independent studies. 
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Figure 3.  DNA vaccination induces strong CD8 and CD4 T cell responses.  BALB/c (A), 
C57Bl/6 (B) or HLA-A2 transgenic (C) mice immunised with DNA constructs expressing RBD 
alongside N linked to modified Fc (iV1) and T cell responses monitored by IFNγ ELISpot 
assay to RBD or N peptide pools and individual peptides.  Symbols represent mean 
response for individual mice, line represents mean value between mice. Data is collated 
from multiple independent studies and p values shown are compared to media control. D, 
Responses from HLA-A2 transgenic mice to RBD 417-425 or N 138-146 peptides assessed 
in the presence of CD4 or CD8 blocking antibodies.  E, Responses from BALB/c mice to 
RBD 505-524 (i) or N 80-100 (ii) peptides assessed in the presence of CD4 or CD8 blocking 
antibodies.  Results are representative of at least two independent experiments in which n=3 
mice per group. Responses are measured as spots/million splenocytes. 
 
Figure 4.  Multi-cytokine T cell responses with Th1 polarisation.  Intracellular cytokine 
staining for IFNγ, TNFα, IL-10 and IL-4 in response to peptide restimulation or stimulation 
with anti-CD3 antibody positive control on splenocyte cultures expanded in vitro with S1 and 
N proteins (A and C) or RBD 505-524 peptide (B) from BALB/c (A and B) or C57Bl/6 (C) 
mice immunised with DNA construct expressing RBD alongside N linked to modified Fc 
(iV1).  Example staining plots (i) and percentage of CD4+ or CD8+ cells are shown (ii). 
 
Figure 5.  DNA vaccination induces anti-RBD neutralising and anti-N antibody responses.  
Sera from immunised mice analysed for anti-S1 (A) or anti-N (D) antibodies by ELISA.  Data 
presented shows absorbance readings with sera titrations (i) and as total µg/mL specific IgG 
(ii) EC50 values were calculated and the quantity of Ig in the sera was estimated from the OD 
value at a 1 in 3000 serum dilution using the standard curve of commercial murine S1 or N 
antibody.  
Sera from BALB/c mice immunised with constructs containing the RBD monomer, trimer or 
monomer linked to Fc (B), C57Bl/6 mice immunised with construct containing the RBD 
monomer or whole S protein (C) and the NIBSC 20/136 standard were assessed for 
neutralisation at increasing sera dilutions (i) and ID50 values (ii). 
 
Figure 6.  DNA vaccination induces cross reactive antibody and T cell responses.  BALB/c 
mice were immunised with DNA constructs expressing original (A-F), B.1.351 (Beta) variant 
(B-F) RBD alongside N linked to modified Fc (iV1) or whole S DNA (B and C).  Sera from 
immunised mice were analysed for anti-S1 antibodies by ELISA using variant S1 proteins (A 
and B), in ACE2 binding inhibition assay versus RBD or whole S protein (Meso Scale 
Discovery Platform) (C), in pseudotype neutralisation assay (D) or live virus neutralisation 
assay (E).  Data are readings at different sera titrations and are representative of multiple 
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experiments.  F, T cell responses in immunised mice monitored by IFNγ ELISpot assay to 
RBD or N peptide pools.  Symbols represent mean response for individual mice, line 
represents mean value between mice. Data are collated from multiple independent studies. 
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